Leonabio Stock Performance
| LONA Stock | 5.88 0.16 2.80% |
LeonaBio holds a performance score of 8 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -1.31, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning LeonaBio are expected to decrease by larger amounts. On the other hand, during market turmoil, LeonaBio is expected to outperform it. Use LeonaBio sortino ratio, semi variance, rate of daily change, as well as the relationship between the value at risk and kurtosis , to analyze future returns on LeonaBio.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in LeonaBio are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, LeonaBio sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.6 | Five Day Return (2.22) | Year To Date Return (17.82) | Ten Year Return (96.66) | All Time Return (96.66) |
Last Split Factor 1:10 | Last Split Date 2025-09-18 |
1 | Athira Pharma, Inc. announced that it expects to receive 89.724073 million in funding - marketscreener.com | 12/18/2025 |
2 | Disposition of 3667 shares by Worthington Mark of LONA New subject to Rule 16b-3 | 12/31/2025 |
3 | Disposition of 876 shares by Worthington Mark of LONA New at 6.88 subject to Rule 16b-3 | 01/02/2026 |
4 | Disposition of 3667 shares by Church Kevin of LONA New subject to Rule 16b-3 | 01/05/2026 |
5 | Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker LONA - Investing News Network | 01/09/2026 |
6 | Disposition of 8526 shares by Church Kevin of LONA New at 0.2935 subject to Rule 16b-3 | 01/16/2026 |
7 | Biopharma deal veteran to drive LeonaBios Phase 3 breast cancer drug - Stock Titan | 02/03/2026 |
8 | ATHA Energy Provides Post CAD 63 Million Financing Plans - Focused on Growth and Discovery at the Angilak Uranium Project | 02/09/2026 |
| Begin Period Cash Flow | 91.2 M | |
| Total Cashflows From Investing Activities | 54.8 M |
LeonaBio Relative Risk vs. Return Landscape
If you would invest 385.00 in LeonaBio on December 3, 2025 and sell it today you would earn a total of 187.00 from holding LeonaBio or generate 48.57% return on investment over 90 days. LeonaBio is currently generating 0.998% in daily expected returns and assumes 9.3195% risk (volatility on return distribution) over the 90 days horizon. In different words, 83% of stocks are less volatile than LeonaBio, and 80% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
LeonaBio Target Price Odds to finish over Current Price
The tendency of LeonaBio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 5.88 | 90 days | 5.88 | about 36.0 |
Based on a normal probability distribution, the odds of LeonaBio to move above the current price in 90 days from now is about 36.0 (This LeonaBio probability density function shows the probability of LeonaBio Stock to fall within a particular range of prices over 90 days) .
LeonaBio Price Density |
| Price |
Predictive Modules for LeonaBio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as LeonaBio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.LeonaBio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. LeonaBio is not an exception. The market had few large corrections towards the LeonaBio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold LeonaBio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of LeonaBio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.79 | |
β | Beta against Dow Jones | -1.31 | |
σ | Overall volatility | 1.20 | |
Ir | Information ratio | 0.07 |
LeonaBio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of LeonaBio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for LeonaBio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| LeonaBio is way too risky over 90 days horizon | |
| LeonaBio appears to be risky and price may revert if volatility continues | |
| LeonaBio was previously known as Athira Pharma and was traded on NASDAQ Exchange under the symbol ATHA. | |
| Net Loss for the year was (96.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| LeonaBio generates negative cash flow from operations | |
| LeonaBio has a poor financial position based on the latest SEC disclosures | |
| About 69.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: ATHA Energy Provides Post CAD 63 Million Financing Plans - Focused on Growth and Discovery at the Angilak Uranium Project |
LeonaBio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of LeonaBio Stock often depends not only on the future outlook of the current and potential LeonaBio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. LeonaBio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3.8 M | |
| Cash And Short Term Investments | 51.3 M |
LeonaBio Fundamentals Growth
LeonaBio Stock prices reflect investors' perceptions of the future prospects and financial health of LeonaBio, and LeonaBio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on LeonaBio Stock performance.
| Return On Equity | -0.89 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 28.62 M | ||||
| Shares Outstanding | 9.34 M | ||||
| Price To Book | 1.98 X | ||||
| EBITDA | (95.81 M) | ||||
| Net Income | (96.94 M) | ||||
| Total Debt | 1.22 M | ||||
| Book Value Per Share | 6.79 X | ||||
| Cash Flow From Operations | (97.17 M) | ||||
| Earnings Per Share | (9.67) X | ||||
| Market Capitalization | 52.56 M | ||||
| Total Asset | 58.78 M | ||||
| Retained Earnings | (406.15 M) | ||||
| Working Capital | 41.71 M | ||||
About LeonaBio Performance
By analyzing LeonaBio's fundamental ratios, stakeholders can gain valuable insights into LeonaBio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if LeonaBio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if LeonaBio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.48) | (1.41) | |
| Return On Capital Employed | (1.99) | (2.09) | |
| Return On Assets | (1.48) | (1.41) | |
| Return On Equity | (2.49) | (2.36) |
Things to note about LeonaBio performance evaluation
Checking the ongoing alerts about LeonaBio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for LeonaBio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| LeonaBio is way too risky over 90 days horizon | |
| LeonaBio appears to be risky and price may revert if volatility continues | |
| LeonaBio was previously known as Athira Pharma and was traded on NASDAQ Exchange under the symbol ATHA. | |
| Net Loss for the year was (96.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| LeonaBio generates negative cash flow from operations | |
| LeonaBio has a poor financial position based on the latest SEC disclosures | |
| About 69.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: ATHA Energy Provides Post CAD 63 Million Financing Plans - Focused on Growth and Discovery at the Angilak Uranium Project |
- Analyzing LeonaBio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether LeonaBio's stock is overvalued or undervalued compared to its peers.
- Examining LeonaBio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating LeonaBio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of LeonaBio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of LeonaBio's stock. These opinions can provide insight into LeonaBio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for LeonaBio Stock analysis
When running LeonaBio's price analysis, check to measure LeonaBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LeonaBio is operating at the current time. Most of LeonaBio's value examination focuses on studying past and present price action to predict the probability of LeonaBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LeonaBio's price. Additionally, you may evaluate how the addition of LeonaBio to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |